Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Prostate Cancer Metastatic × olaparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 23 Breast Neoplasms 13 Neoplasms 9 Triple Negative Breast Neoplasms 6 Prostatic Neoplasms 6 Sarcoma 5 Pancreatic Neoplasms 5 Fanconi Anemia, Complementation Group D1 5 Endometrial Neoplasms 5 Small Cell Lung Carcinoma 4 Neoplasm Metastasis 4 Colorectal Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Recurrence 3 Fallopian Tube Neoplasms 3 Stomach Neoplasms 2 Rhabdomyosarcoma 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Metastatic Castration-resistant Prostate Cancer 2 Glioma 2 Central Nervous System Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma 2 Advanced Solid Tumours 2 Advanced Solid Tumors 2 Wilms Tumor 1 Urinary Bladder Neoplasms 1 Triple Negative Metastatic Breast Cancer 1 Solid Tumor 1 Smoking 1

Interventions

enzalutamide 4 cabazitaxel 4 Prednisone 4 XRP6258 2 Docetaxel 2 sipuleucel-T 1 rucaparib 1 olaparib 1 Zuclomiphene 1 Prednisolone 1 Lenograstim 1 LY3023414 1 Injections 1 Hematologic Tests 1 Granulocyte Colony-Stimulating Factor 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03434158 2022-11-03

IMANOL

Spanish Oncology Genito-Urinary Group

Phase 2 Completed

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡